[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100086638":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":16,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":60,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Aliskiren\u002FHCTZ",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,29],{"facility":14,"status":7,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"East Hanover","New Jersey","07936","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-74.36487,40.8201,{"lat":27,"lon":26},{"facility":7,"status":7,"city":30,"state":7,"zip":7,"country":31,"countryCode":32,"cosmosGeoPoint":7,"geoPoint":7,"contacts":7},"Investigative Centers","Germany","DE",{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100086638","phase-3-a-safety-and-efficacy-trial-of-the-combination-of-aliskiren--hydrochlorothiazide-hctz300125-mg-and-30025-mg-compared-to-aliskiren-300-mg-in-hypertensive-patients-100086638",false,"NCT00386139","A Safety and Efficacy Trial of the Combination of Aliskiren \u002F Hydrochlorothiazide (HCTZ)(300\u002F12.5 mg and 300\u002F25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients","An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren \u002F HCTZ (300\u002F12.5 mg and 300\u002F25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy","Inclusion Criteria:\n\n* Male or female outpatients 18 years old or older.\n* Patients with a diagnosis of hypertension.\n* Patients who are eligible and consent to participate in the study\n\nExclusion Criteria:\n\n* Severe hypertension\n* Previous or current diagnosis of heart failure.\n* History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":45,"type":46},881,"ACTUAL","INTERVENTIONAL",[49],"PHASE3","Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.",[52],"Hypertension",[54,55,56,57,58,59],"Diastolic","systolic","hypertension","aliskiren","blood pressure","hydrochlorothiazide, HCTZ","COMPLETED","2017-02-03",{"date":63,"type":64},"2017-02-07","ESTIMATED",{"date":66,"type":7},"2006-09",{"date":68,"type":46},"2007-07",{"name":5,"class":6},2]